Skip to content
Biotechnology

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Demand for Genetic Optimization Continues to Expand

Nucleus Genomics Inc. 3 mins read

The partnership brings Nucleus’ advanced carrier and embryo screening to Hawaii’s largest IVF practice

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Nucleus Genomics today announced an IVF+ partnership with the Fertility Institute of Hawaii, bringing its advanced carrier screening and embryo analysis to Hawaii's largest IVF practice.

Through the collaboration, patients will gain deeper genetic insight into their embryos during IVF, including risks tied to cancers, heart disease, and diabetes — conditions that are especially prevalent across the Pacific. It will also expand access to Nucleus for many international patients who travel to Hawaii for fertility care from Japan, Korea, China, Australia, and New Zealand.

Based in Honolulu and founded by Dr. John Frattarelli, the Fertility Institute of Hawaii has been a leader in fertility care for more than two decades. Having supported thousands of families, its doctors have helped bring more than 15,000 babies into the world.

“When choosing which embryo to transfer, patients want more information during IVF,” said Dr. Nathan Treff, Chief Clinical Officer at Nucleus Genomics. “The Fertility Institute of Hawaii has helped families across Hawaii and the Pacific for decades. We’re excited to work alongside a team so deeply trusted by its patients and community.”

Building on decades of genetic research, Nucleus offers advanced genetic insight across family planning and IVF through its services Preview and Embryo. Together, these help prospective parents better understand inherited disease risk, screening for more than 2,000 genetic conditions and traits. This includes insight into many conditions not typically offered in IVF, including endometriosis, type 1 diabetes, breast cancer, heart disease and Alzheimer’s disease.

When using its genetic optimization models, the company showed that prospective parents selecting among five embryos can expect average relative risk reductions of 31.9% for endometriosis, 67% for type 1 diabetes, 42% for breast cancer, 35% for heart disease, and 55% for Alzheimer’s disease.

"The future of IVF is genomic. Our partnership with Nucleus reflects what we've always believed: patients in Hawaii shouldn't have to leave home or settle for less,” said Dr. John Frattarelli, Founder, CEO, and Medical Director, Fertility Institute of Hawaii. “We're proud to be the first in the state to offer this level of embryo genetic analysis, and even prouder that it enables our local and international patients to make their most consequential decisions with the most complete information available."

Nucleus’ partnership with the Fertility Institute of Hawaii also comes at a time of significant international patient interest for the company’s services, especially from Asia, Australia and New Zealand. It also comes amid rapid growth for Nucleus, which in recent months announced clinic partnerships in California, New York, India and the Middle East.

Today, Nucleus has a waitlist of more than 3,000 patients and continues to rapidly expand its IVF+ Clinic Network. As more fertility clinics adopt advanced genomics, Nucleus is helping establish a new standard for how families plan for the next generation.

Press Contact
Nucleus Genomics
[email protected]

About Nucleus Genomics
Nucleus Genomics helps couples plan and have their best baby. Its services span advanced carrier screening, embryo analysis, and an integrated IVF care experience, with a focus on building generational health. Nucleus has raised more than $32 million to date with investors including Founders Fund, Seven Seven Six, Samsung Next, and Quiet Capital. To learn more, visit https://mynucleus.com.

About Fertility Institute of Hawaii
Fertility Institute of Hawaii is the largest and most comprehensive IVF practice in Hawaii, based in Honolulu and serving patients across the Hawaiian Islands and internationally, including families from Japan, Korea, Australia, and New Zealand. At the heart of the clinic is an on-site, state-of-the-art IVF laboratory, enabling the most advanced reproductive technologies and cutting-edge genetic testing services all under one roof. From IVF and fertility preservation to personalized reproductive care, Fertility Institute of Hawaii delivers a full spectrum of fertility services with the clinical expertise and compassionate support that every family deserves.


Primary Logo

More from this category

  • Biotechnology
  • 11/06/2026
  • 08:06
AusBiotech

Seventy-six per cent of biotech, medtech and health tech companies surveyed reveal they will be worse off under R&D Tax Incentive changes

11 June 2026 More than three quarters of Australia’s biotech,medtech and health tech companies recently surveyed said they will be significantly or moderately negatively impacted by theproposed Budget changes to the R&D Tax Incentive (RDTI), with many actively considering relocating overseas, or moving lifesaving clinical trials, due to the controversial reforms. The proposal to limit the RDTI’s long standing refundable tax offset for companies less than 10 years old is not fit-for-purpose and does not cater to the realities of the sector. The development of a new medicine, vaccine or advanced therapeutic routinely takes well in excess of a decade.…

  • Biotechnology
  • 10/06/2026
  • 15:17
CUKTECH Technology Co., Ltd.

China’s Leading Brand CUKTECH has Cumulatively Sold Over 150 Million Power Banks Globally, Taking a Further Step Towards Globalization

CANBERRA, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Latest data from CUKTECH, a leading Chinese brand, shows that it has cumulatively shipped over 150 million power banks and 20 million chargers. As technology becomes increasingly integrated into daily life, companies are exploring how innovation can genuinely enhance everyday experiences. CUKTECH is a technology-driven innovator guided by its philosophy of “Instant Charge” dedicated to creating a comprehensive clean energy ecosystem and services for users around the world.Since its founding, CUKTECH has placed research and development at the core of its operations. Over 50% of its employees work in R&D and Quality…

  • Biotechnology
  • 06/06/2026
  • 08:05
AusBiotech

Opposition to proposed R&D Tax Incentive change unites Australia’s biotech, medtech and health tech sector

6 June 2026 Proposed Budget changes to the Research and Development Tax Incentive (RDTI) will disproportionally impact Australia’s biotech, medtech and health tech sector forcing more home-grown companies to consider moving overseas. Nine leading health and life sciences organisations: AusBiotech, Pathology Technology Australia, MTPConnect, ANDHealth, Life Sciences Queensland, Life Sciences WA, BioNSW, BioMelbourne Network and ARCS Australia, have co-signed a letter to Treasurer Jim Chalmers asking for an urgent review of RDTI changes proposed in the Federal Budget. While the sector shares concerns regarding a number of tax changes including to CGT, a proposal to limit the RDTI’s long standing…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.